- Home
- Latest news
Latest news
What you need to know about Johnson & Johnson’s 2024 fourth-quarter and full-year earnings report
Check out this infographic breakdown of the company’s fourth-quarter and full-year performance, with highlights from its Innovative Medicine and MedTech businesses.
How Johnson & Johnson is working to get medications to people around the world who need them most
In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.
More from Johnson & Johnson
After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists
Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.
Johnson & Johnson named a 2025 Fortune World’s Most Admired Company
A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.
Careers
Looking for a career opportunity at Johnson & Johnson? Search our available jobs.
Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health
Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
6 ways Johnson & Johnson is using AI to help advance healthcare
Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.
Press releases
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction
Johnson & Johnson MedTech Celebrates Inaugural National Heart Recovery Awareness Day
Impella patients share stories of heart recovery at reunions, events across the country Launch of Boston’s first hands-only CPR kiosk with American Heart Association
Johnson & Johnson to Resume U.S. VARIPULSE™ Cases
Investigation found that VARIPULSE™ devices operate as intended Cases being performed in U.S. External Evaluation to resume and Instructions for Use to be updated
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions
Johnson & Johnson Statement on Phase 3 E.mbrace Study
Independent, scheduled review finds investigational vaccine regimen lacks efficacy in preventing invasive E. coli disease (IED) No safety signals identified
Johnson & Johnson MedTech Launches CEREGLIDE™ 92 Catheter System for Acute Ischemic Stroke
Next-generation .092” catheter now available in U.S.
